相关实验视频
Updated: Feb 20, 2026

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
23.2K
帕金森病多模式综合治疗 (PD-MCT) 的综合影响:一项两中心前性试验
Isabel Friedrich1, Laura Gutschow2,3, David Weise4
1Department of Neurology, University of Leipzig Medical Centre, Liebigstrasse 20, 04103, Leipzig, Germany. Isabel.Friedrich@medizin.uni-leipzig.de.
Journal of neurology
|February 18, 2026
概括
住院帕金森病多模式综合治疗 (PD-MCT) 在晚期帕金森病中显著改善了运动和非运动症状,认知和生活质量. 基线症状严重程度较高的患者从这种密集治疗中获得了最大的益处.
科学领域:
- 神经学 神经学
- 神经退行性疾病 神经退行性疾病
- 运动障碍 运动障碍
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,通过运动和非运动症状影响生活质量.
- 住院帕金森病多模式综合治疗 (PD-MCT) 结合了药物调整和密集的多专业疗法.
- 关于PD-MCT最受益的特定症状领域和PD晚期治疗反应的预测因素的证据有限,特别是在认知状态方面.
研究的目的:
- 评估住院PD-MCT在晚期异常发病帕金森病中的有效性.
- 确定哪些症状领域 (运动,非运动,认知,生活质量) 显示出最显著的改善.
- 确定预测PD-MCT治疗反应的患者特征.
主要方法:
- 这是一项双中心前性队列研究,涉及53名患有晚期异常病理病的成年人.
- 患者接受了14-21天的住院PD-MCT.
- 评估包括运动功能 (MDS-UPDRS),非运动症状,认知和生活质量 (PDQ-39) 在基线,出院前和3个月后的随访.
主要成果:
- PD-MCT显著改善了运动症状严重程度,整体运动功能和生活质量.
- 在非运动症状,认知,情绪和功能指标方面观察到额外的益处.
- 较大的基线运动障碍和较差的生活质量预测了更大的短期改善;基线认知没有显著影响有效性.
结论:
- 住院PD-MCT在高级PD中提供了在运动,非运动,认知和生活质量领域的临床意义上的好处.
- 观察到最强的治疗效应是在具有高起始症状负担的患者身上.
- 基线运动得分显示,运动症状严重程度的改善具有适度的预测值.
相关概念视频
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Drug Therapy
316
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
316
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

